We compared subtypes of papillary renal cell carcinoma (pRCC; types 1 and 2) and clear cell renal cell carcinoma (ccRCC) in patients with T1-stage RCC to analyze the impact of the subtype on oncological outcomes. Materials and Methods: This paper reviewed 75 patients with pRCC and 252 patients with ccRCC at T1-stage from 1998-2012. Thus, we assessed the impact of subtype on oncologic outcomes among patients with T1-stage RCC. We used Kaplan-Meier analysis to estimate the overall survival and recurrence-free survival The median follow-up duration was 95 months (interquartile range, 75.4-119.3 months).
INTRODUCTION
Renal cell carcinoma (RCC) constitutes approximately 2%-3% of all cancers, and its highest occurrence rate is in western countries. 1 The current understanding of the pathogenesis of renal neoplasm has been established by World Health Organization classification 2 and Mainz 3 and Heidelberg classifications. 
Pathological evaluation
The 
Follow-up strategy
Abdominal and pelvic CT or MRI was performed at least every 6 months during the first year. Annual follow-up was done to trace the presence of local recurrence and distant metastasis. Blood sampling and chest X-rays were conducted during the follow-up periods. Chest CT and bone scans were also done if the surgeon deemed them necessary; the median 
Statistical analysis
The tumor characteristics were compared using Pearson Table 2 ).
The 5-year recurrence-free survival rates of pRCC and ccRCC were 95.4% and 97.6%, respectively. pRCC was worse than ccRCC for recurrence-free survival (p=0.008), the 5-year overall survival rates of pRCC and ccRCC were 88.5% and 95.2%, respectively (p=0.32). There was no significant statistical difference in the overall survival rate between pRCC and ccRCC ( Fig. 1) . The 6-year recurrence-free survival rates of type 1 pRCC and type 2 pRCC were 95.3% and 93.5%, respectively (p=0.526). The 5-year overall survival rates of type 1 pRCC and type 2 pRCC were 81.5% and 88.9%, respectively (p=0.701). There was no significant statistical difference between type 1 pRCC and type 2 pRCC for either recurrence-free survival or overall survival (Fig. 2 ).
Univariate and multivariate Cox proportional hazard models 
DISCUSSION
In 1996, Heidelberg conference members made the first consensus in the identification of different types of RCC based on genetic differences. The Heidelberg classification system defines four different tumor types: clear cell, papillary, chromophobe, and collecting duct; there is also a group of tumors that remain unclassified. 4 ccRCC is the most common histological subtype, accounting for 75%-80% of all RCCs. 6, 16 pRCC is the second most common subtype, accounting for 10%-15% of all malignant renal neoplasms. pRCC is histologically and genetically subclassified as types 1 and 2.
10, [17] [18] [19] Tumor stage and nuclear grade are the most important prognostic factors for determining the oncologic outcomes of RCC.
The prognostic significance of RCC subtype has been studied previously with variable patient populations; despite these multiple studies, the results are inconsistent. Therefore, it is controversial whether the histological subtype itself contributes to the oncologic outcome. A multicenter study with 4,063 patients from eight international centers reported a better 5-year cancer-specific survival rate for patients with pRCC (79%) than for those with ccRCC (73%) on univariate analysis. 9 On multivariate analysis, the histological subtype was not an independent prognostic factor. A similar result was obtained in Among the 75 pRCC patients in this study, 6 had tumor recurrence; of these, 3 were the type 1 subtype of pRCC, and the other 3 were in the type 2 pRCC subgroup. Meanwhile, should be confirmed using larger prospective settings.
CONCLUSION
Histological subtype (pRCC vs. ccRCC) impacted recurrence-free survival but not overall survival in T1-stage.
pRCC has an aggressive oncologic outcome concerning recurrence after surgery. The subtypes of pRCC (types 1 and 2)
had no impact on either recurrence-free survival or overall survival. Close observation of recurrence and long-term follow-up is recommended particularly among patients with T1-stage pRCC patients.
